https://www.selleckchem.com/products/TW-37.html
BACKGROUND COPD is a heterogeneous disease and patients may respond differently to therapies depending on baseline symptom burden. METHODS This post-hoc analysis from the 52-week FLAME study investigated the impact of baseline symptom burden in terms of health status, dyspnoea, bronchitis status, eosinophil levels and smoking status on the subsequent risk of moderate or severe exacerbations. Health status was measured by St. George's Respiratory Questionnaire (SGRQ) score (higher ≥46.6 and lower less then 46.6) and COPD Assessment Test (
Like
Comment
Share
